Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Accutar Starts China Trial of Oral Chimeric Degrader for Prostate Cancer

publication date: Feb 23, 2023

Accutar Biotechnology enrolled the first patient in a China Phase I trial of AC0176, an oral chimeric degrader molecule aimed at Androgen Receptor (AR) protein in patients with metastatic Castration Resistant Prostate Cancer (mCRPC). The company uses its AI-based platform to discover drug candidates with greater high potency and selectivity. Accutar is already testing AC0176 in the US. In 2022, the New Jersey-Shanghai company started China trials for a breast cancer candidate, a chimeric degrader molecule designed to target ERα protein. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital